

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
18184-0018-01-USSERIAL NO.
10/578,522**INFORMATION DISCLOSURE CITATION**

APPLICANT:

Steven M. Leventer, *et al*

FILING DATE May 8, 2006

GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/AH/	AA	WO 02/088096	07 Nov 2002	PCT		X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/AH/	AB	LEVENTER, S. M., et al., "The Potential of Dextofisopam for Treatment of Irritable Bowel Syndrome and Inflammatory Bowel Disease", American Journal of Gastroenterology, pp. S279 (2004)
/AH/	AC	KONO, T., et al., "Clinical Evaluation of Tofisopam Grandaxin on Several Dermatological Diseases in Patients with Psychosomatic Symptoms", HIFU, 33:6, pp. 699-707 (1991)
/AH/	AD	SZEKELY, J. I., et al., "Apparent antinociceptive and anti-inflammatory effects of GYKI 52466", European Journal of Pharmacology, 336, pp. 143-154 (1997)
/AH/	AE	Nedogoda, S. V., et al., "Treatment of irritable bowel syndrome with dicetelium and spasmomen, Klinicheskaia meditsina. 78:10, pp 42-46 (2000)
/AH/	AF	Sato, M., et al., "Effects of Tofisopam on Gastric Functions in Rats", Folia Pharmacologica Japonica, 79:4, pp. 307-316, (1982),

EXAMINER

/Alicia Hughes/

DATE CONSIDERED

03/13/2010

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.